Drug-induced cardiac arrest: a pharmacovigilance study from 2004–2024 based on FAERS database
Arzneimittelinduzierter Herzstillstand: pharmakovigilanzbasierte Studie von 2004–2024 auf Grundlage der FAERS-Datenbank
Frontiers in Cardiovascular Medicine · 01.05.2025 · 12
DOI: 10.3389/fcvm.2025.1498700 ↗Auf einen Blick
In FAERS wurden Berichte zu Herzstillstand zwischen dem ersten Quartal 2004 und dem zweiten Quartal 2024 ausgewertet. Für 43 von 82 Arzneimitteln mit über 100 Berichten zeigten sich positive Signale.
Fragestellung
Welche Arzneimittel sind in FAERS mit einem erhöhten Risiko für Herzstillstand assoziiert?
Methode
Pharmakovigilanzstudie mit FAERS-Daten von 2004 bis 2024; Signaldetektion mit ROR und PRR.
Ergebnisse
66.431 Berichte; 34.508 Männer (51,9 %) und 31.923 Frauen (48,1 %). 71,8 % der Fälle wurden von Gesundheitsfachpersonen gemeldet, 67,2 % führten zum Tod. Top-5 nach ROR: carisoprodol 34,13 (95 %-KI 29,62–39,32), sugammadex 26,93 (22,56–32,16), regadenoson 20,00 (17,69–22,60), alprazolam 12,82 (12,19–13,48), propofol 11,93 (10,61–13,41).
Schlussfolgerung der Autor:innen
Die Studie identifiziert über 40 Arzneimittel mit potenziell erhöhtem Risiko für Herzstillstand auf Basis von FAERS-Daten. Die Autor:innen betonen erhöhte Wachsamkeit bei der Verordnung und engmaschige kardiale Überwachung.
Kernaussagen
- 66.431 FAERS-Berichte zu Herzstillstand wurden analysiert.
- 43 von 82 Arzneimitteln zeigten positive Signale.
- Top-5 nach ROR: carisoprodol, sugammadex, regadenoson, alprazolam, propofol.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 01.05.2025. Verfasst von Gaocan Ren und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Disease, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Reanimation
Abstract (Originalsprache)
Objective
Utilizing the FDA Adverse Event Reporting System (FAERS) database, this study conducts signal detection for drugs associated with cardiac arrest (CA), aiming to optimize clinical decision-making and ensure safer drug usage.
Methods
Adverse event reports related to CA from the first quarter of 2004 to the second quarter of 2024 were extracted from the FAERS database. Signal detection was conducted using the reporting odds ratio (ROR) and proportional reporting ratio (PRR) to identify drugs associated with an increased risk of CA.
Results
A total of 66,431 reports were analyzed, comprising 34,508 males (51.9%) and 31,923 females (48.1%). The majority of cases (71.8%) were reported by healthcare professionals, with adults (≥18 years old) representing the predominant group. Clinical outcomes showed that 67.2% of cases resulted in death. Out of 82 drugs with over 100 CA-related reports, 43 displayed positive signals. The top five drugs identified by ROR were: carisoprodol [ROR (95% CI): 34.13 (29.62–39.32)], sugammadex [ROR (95% CI): 26.93 (22.56–32.16)], regadenoson [ROR (95% CI): 20.00 (17.69–22.60)], alprazolam [ROR (95% CI): 12.82 (12.19–13.48)], and propofol [ROR (95% CI): 11.93 (10.61–13.41)]. In the system drug signal detection, musculo-skeletal system drugs ranked highest [ROR (95% CI): 30.99 (27.74–34.62)], followed by alimentary tract and metabolism drugs [ROR (95% CI): 4.75 (4.59–4.92)], nervous system drugs [ROR (95% CI): 4.51 (4.4–4.61)], anti-infective drugs [ROR (95% CI): 4.13 (3.74–4.57)], cardiovascular drugs [ROR (95% CI): 3.89 (3.78–4.01)], and antineoplastic and immunomodulating agents [ROR (95% CI): 2.16 (2.13–2.2)].
Conclusion
This study identifies over 40 drugs potentially associated with an elevated risk of CA based on FAERS data. Healthcare professionals should be particularly vigilant when prescribing these drugs, especially to patients with a history of heart disease, and ensure rigorous monitoring of their cardiac health.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Disease, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
- Graduate School, China Academy of Chinese Medical Sciences, Beijing, China.
- Graduate School, Beijing University of Chinese Medicine, Beijing, China.
- Graduate School, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
- National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
- State Key Laboratory of Traditional Chinese Medicine Syndrome, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Zitieren
APA
Ren, G., Huang, P., Zhang, J., Liu, J., Yan, Z., & Ma, X. (2025). Drug-induced cardiac arrest: a pharmacovigilance study from 2004–2024 based on FAERS database. Frontiers in Cardiovascular Medicine, 12. https://doi.org/10.3389/fcvm.2025.1498700
Vancouver
Ren G, Huang P, Zhang J, Liu J, Yan Z, Ma X. Drug-induced cardiac arrest: a pharmacovigilance study from 2004–2024 based on FAERS database. Frontiers in Cardiovascular Medicine. 2025;12. doi:10.3389/fcvm.2025.1498700
BibTeX
@article{Ren2025,
author = {Ren, Gaocan and Huang, Pingping and Zhang, Jinhui and Liu, Jin and Yan, Zian and Ma, Xiaochang},
title = {Drug-induced cardiac arrest: a pharmacovigilance study from 2004–2024 based on FAERS database},
journal = {Frontiers in Cardiovascular Medicine},
year = {2025},
volume = {12},
doi = {10.3389/fcvm.2025.1498700}
}
EUVIMED